Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.79 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valine SCHEMBL6267142 | 0.97 | SLC7A5 (0.83) | SLC7A5SLC1A3SLC1A2SLC1A1LMNA | |
| Valine SCHEMBL8850083 | 0.92 | SLC7A5 (0.94) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL15602719 | 0.89 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1LMNA | |
| Valine SCHEMBL27571970 | 0.89 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1LMNA | |
| Valine SCHEMBL482773 | 0.89 | SLC7A5 (0.88) | SLC7A5SLC1A3SLC1A2SLC1A1LMNA | |
| Valine SCHEMBL8516 | 0.89 | — | — | |
| Valine SCHEMBL41225 | 0.89 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL43678 | 0.89 | — | — | |
| Valine SCHEMBL1813972 | 0.89 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Valine SCHEMBL288203 | 0.89 | SLC7A5 (1.00) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897153-A1 | ISOLATION OF FUNGAL MELANIN AND USES IN EXTERNAL RADIATION SHIELDING AND HEAT CAPTURE | The Johns Hopkins University (US) | 2021-10-27 | — | — | EP | claimed |
| WO-2020132555-A1 | ISOLATION OF FUNGAL MELANIN AND USES IN EXTERNAL RADIATION SHIELDING AND HEAT CAPTURE | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-06-25 | — | — | WO | claimed |
| US-20230172903-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GENZYME CORPORATION | 2023-06-08 | — | — | US | disclosed |
| US-20210393590-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GENZYME CORP (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210369672-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GENZYME CORP (US) | 2021-12-02 | — | — | US | disclosed |
| EP-3898170-A1 | MELANIN BASED BIO-COMPOSITES FOR 3D PRINTING | The Johns Hopkins University (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3897153-A1 | ISOLATION OF FUNGAL MELANIN AND USES IN EXTERNAL RADIATION SHIELDING AND HEAT CAPTURE | The Johns Hopkins University (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3896069-A1 | PHARMACEUTICAL COMPOSITION OF THE GLUCOSYLCERAMIDE SYNTHASE INHIBITOR ELIGLUSTAT FOR THE TREATMENT GAUCHER'S DISEASE COMPRISING ADJUSTING THE INDIVIDUAL THERAPEUTICAL DOSE TO THE P450 METABOLISM OF THE PATIENT | Genzyme Corporation (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3599237-B1 | PHARMACEUTICAL COMPOSITION OF THE GLUCOSYLCERAMIDE SYNTHASE INHIBITOR ELIGLUSTAT FOR THE TREATMENT OF GAUCHER'S DISEASE COMPRISING ADJUSTING THE INDIVIDUAL THERAPEUTICAL DOSE TO THE P450 METABOLISM OF THE PATIENT | GENZYME CORP (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-2504332-B2 | AN AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE | GENZYME CORP (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10888547-B2 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | GENZYME CORPORATION (US) | 2021-01-12 | — | — | US | disclosed |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20060037104-A1 | Modified cottonseed oil | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION | 2006-02-16 | — | — | US | disclosed |
| US-6974898-B2 | Method of modifying the content of cottonseed oil | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2005-12-13 | — | — | US | disclosed |
| US-20050107597-A1 | Polypeptides of pseudomonas aeruginosa | ID BIOMEDICAL CORPORATION (CA) | 2005-05-19 | — | — | US | disclosed |
| EP-1282709-A4 | METHOD OF MODIFYING THE CONTENT OF COTTONSEED OIL | COMMW SCIENT IND RES ORG (AU) | 2005-01-19 | — | — | EP | disclosed |
| US-20040132652-A1 | Pharmaceutical compositions | SHIRE BIOCHEM INC. (CA) | 2004-07-08 | — | — | US | disclosed |
| EP-1282709-A1 | METHOD OF MODIFYING THE CONTENT OF COTTONSEED OIL | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-02-12 | — | — | EP | disclosed |
| US-20020104124-A1 | Method of modifying the content of cottonseed oil | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-08-01 | — | — | US | disclosed |
| WO-2001079499-A1 | METHOD OF MODIFYING THE CONTENT OF COTTONSEED OIL | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393590-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GBA1, UGCG, GBA2 | SLC7A5 951/4885SLC1A3 1628/4885SLC1A2 1816/4885 |
| US-20230172903-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GBA1, UGCG, GBA2 | SLC7A5 833/4885SLC1A3 1620/4885SLC1A2 1795/4885 |
| US-20210369672-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | GBA1, UGCG, GBA2 | SLC7A5 833/4885SLC1A3 1620/4885SLC1A2 1795/4885 |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | NGLY1, PHOSPHO1, LPXN | SLC7A5 2535/4885SLC1A3 3556/4885SLC1A2 4141/4885 |
| US-10888547-B2 | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase | GBA1, GBA2, UGCG | SLC7A5 877/4885SLC1A3 2260/4885SLC1A2 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.